Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation

M. I. H. Al-Jazairi · M. Rienstra · T. J. Klinkenberg · M. A. Mariani · I. C. Van Gelder · Y. Blaauw

Published online: 4 February 2019
© The Author(s) 2019

Abstract

Background Combined ‘hybrid’ thoracoscopic and percutaneous atrial fibrillation (AF) ablation is a strategy used to treat AF in patients with therapy-resistant symptomatic AF. We aimed to study efficacy and safety of single-stage hybrid AF ablation in patients with symptomatic persistent AF, or paroxysmal AF with failed endocardial ablation, and assess determinants of success and quality of life.

Methods We included consecutive patients undergoing single-stage hybrid AF ablation. First, we performed epicardial ablation, via thoracoscopic access, to isolate the pulmonary veins and superior caval vein and to create a posterior left atrial box. Thereafter, isolation was assessed endocardially and complementary endocardial ablation was performed, followed by cavo-tricuspid isthmus ablation. Efficacy was assessed by 12-lead electrocardiography and 72-hour Holter monitoring after 3, 6 and 12 months. Recurrence was defined as AF/atrial flutter/tachycardia recorded by electrocardiography or Holter monitoring lasting >30 s during 1-year follow-up.

Results Fifty patients were included, 57 ± 9 years, 38 (76%) men, 5 (10%) paroxysmal, 34 (68%) persistent and 11 (22%) long-standing persistent AF. At 1-year 38 (76%) maintained sinus rhythm off antiarrhythmic drugs. Majority of recurrences were atrial flutter (9/12 patients). Success was associated with type of AF \( (p=0.039) \). Patients with paroxysmal AF had highest success, patients with longstanding persistent AF had lowest success. Seven (14%) patients had procedure-related complications. Quality of life improved after ablation in patients who maintained sinus rhythm.

Conclusion Success of single-stage hybrid AF ablation was 76% off antiarrhythmic drugs, being associated with type of AF. Quality of life improved significantly. Procedure-related complications occurred in 14%.

Keywords Atrial fibrillation · Hybrid · Ablation · Thoracoscopic · Pulmonary vein isolation · Single-stage

Introduction

At present there is only limited evidence that a rhythm control strategy for atrial fibrillation (AF) improves patients’ mortality and morbidity [1–4]. However, many patients are moderately to severely symptomatic, necessitating a rhythm control strategy [5].

Antiarrhythmic drugs (AADs), often being used as first-line rhythm control strategy [5], are only moderately successful in maintaining sinus rhythm (SR) dur-

What’s new?

- Single-stage hybrid ablation is highly effective in patients with paroxysmal AF after prior failed endocardial ablations.
- Type of AF is the main determinant of single-stage hybrid ablation success.
- Hybrid AF ablation led to improvement in patients’ quality of life.
ing long-term follow-up [6]. Endocardial pulmonary vein isolation (PVI) has now become an established, effective and safe therapy for patients with paroxysmal AF [5, 7]. However, in patients with persistent and long-standing persistent AF, PVI alone is less effective, even after multiple procedures [8], or with the inclusion of additional endocardial ablation lines or targets [9]. This is likely due to advanced electro-anatomic remodelling of the atria and the extra-pulmonary vein triggers being more prominent [10].

The surgical Cox-Maze procedure showed higher success in patients with persistent and long-standing persistent AF [11]. It is, however, a complex and invasive procedure. Hybrid AF ablation combines surgical thoracoscopic epicardial atrial ablation with endocardial atrial catheter ablation. The potential benefit of this combined approach is that incomplete epicardial ablation lines can be completed in the same session, via an endocardial approach. In contrast to the Cox-Maze procedure, thoracoscopic epicardial ablation is less invasive. At present, there is still little data about the outcome of single-stage hybrid AF ablation with few centres reporting conflicting results [12, 13]. Our aim is to investigate the efficacy and safety of hybrid AF ablation at our centre, to explore factors determining its success, and to assess its effect on the quality of life.

**Methods**

**Patient population**

The Hybrid AF Ablation study, Clinicaltrials.gov registration number NCT02516033, is a prospective, single-centre, observational study performed at the University Medical Center Groningen, the Netherlands. A total of 50 consecutive patients were included between January 2015 and June 2016. The institutional review board approved the study protocol, and all patients provided written informed consent. Patients with symptomatic persistent or long-standing persistent AF, or paroxysmal AF with two or more failed catheter ablations were candidates for this procedure. Patients with a history of cardiac surgery, and patients with a body mass index (BMI) of 35 or over were excluded.

**Definitions**

AF was defined as paroxysmal (all AF episodes lasting less than 7 consecutive days), persistent (at least some AF episodes lasting more than 7 consecutive days, but could still spend periods in SR), or long-standing persistent AF (AF episode lasting more than 365 consecutive days) [5].
Table 1  Patient clinical characteristics of study population at baseline (n = 50)

| Characteristic                          | Value       |
|-----------------------------------------|-------------|
| age (years)                             | 57 ± 9      |
| total history of AF (years)             | 5.1 (2.1–8.4) |
| men                                     | 38 (76%)   |
| type of AF                              |             |
| paroxysmal                              | 5 (10%)     |
| persistent                              | 34 (68%)    |
| long-standing                           | 11 (22%)    |
| previous failed catheter ablation(s)    | 25 (50%)    |
| previous CTI ablation                   | 10 (20%)    |
| heart failure                           | 2 (4%)      |
| hypertension                            | 23 (46%)    |
| diabetes mellitus                       | 4 (8%)      |
| coronary artery disease                 | 2 (4%)      |
| stroke or TIA                           | 3 (6%)      |
| CHA2–DS2–VASc score                     | 1 (0–2)     |

**Physical examination**

| Blood pressure (mm Hg)                  | Value       |
|-----------------------------------------|-------------|
| systolic                                | 129 ± 14    |
| diastolic                                | 82 ± 10     |

| BMI (kg/m²)                             | Value       |
|-----------------------------------------|-------------|
| BMI > 30                                 | 12 (24%)    |

| Obesity                                 | Value       |
|-----------------------------------------|-------------|
| (BMI > 30)                               | 12 (24%)    |

| echocardiography                         | Value       |
|-----------------------------------------|-------------|
| interventricular septum thickness (mm)  | 10.6 ± 1.9  |
| LA volume index (ml/m²)                 | 40 ± 11     |
| LVEF (%)                                 | 55 ± 6      |

| Use of antiarrhythmic drugs             | 19 (38%)    |
|-----------------------------------------|-------------|

**AF atrial fibrillation, CHA2–DS2–VASc- congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes mellitus, prior stroke [doubled]-vascular disease age 65–74, sex category, CTI cavotricuspid isthmus, TIA transient ischaemic attack, BMI body mass index, LA left atrial, LVEF left ventricular ejection fraction**

Table 2  Procedural data

| Characteristic                          | Value       |
|-----------------------------------------|-------------|
| rhythm at start of procedure            |             |
| SR                                      | 22 (44%)    |
| AF                                      | 28 (56%)    |
| total procedure time (minutes)          | 396 ± 45    |
| surgical part                           |             |
| patient preparation (minutes)           | 55 ± 12     |
| surgical procedure (minutes)            | 396 ± 45    |
| percutaneous part (minutes)             | 218 ± 73    |
| total number of epicardial applications |            |
| right pulmonary veins                   | 2 ± 2       |
| left pulmonary veins                    | 2 ± 3       |
| superior line                           | 28 ± 13     |
| inferior line                           | 34 ± 16     |
| superior caval vein                     | 2 ± 1       |
| patients undergoing endocardial ablation| 48 (96%)    |
| complete box isolation                  | 21 (42%)    |
| CTI line                                | 41 (82%)    |
| additional lines (to stop AFL/AT)       | 19 (38%)    |
| CFAE ablation (to stop AF)              | 22 (44%)    |
| confirmed box isolation after epicardial ablation | 27 (54%) |
| LAA closure                             | 15 (30%)    |

**CTI cavotricuspid isthmus, SR sinus rhythm, AF atrial fibrillation, AFL atrial flutter, AT atrial tachycardia, CFAE complex fractionated atrial electrogram, LAA left atrial appendage, AADs antiarrhythmic drugs**

Study design

At baseline, we assessed clinical history, physical examination, current medication, an electrocardiogram, blood samples, 24-hour Holter monitoring, echocardiography, cardiac computed tomography scan and quality of life.

Prior to the procedure, a trans-oesophageal echocardiogram was performed to exclude the presence of a thrombus in the left atrium and atrial appendage. Outpatient clinic visits with electrocardiography (ECG) recording were scheduled at 1, 3, 6 and 12 months after procedure. At 3, 6 and 12 months, a 72-hour Holter monitoring was performed. At 12 months, quality of life was re-assessed. During all visits we collected information about AF, atrial flutter (AFL) or atrial tachycardia (AT) recurrences documented by the general practitioner, during emergency room visits or during hospital admissions, as well as adverse events associated with the procedure. AADs were continued during the first 3 months, and then discontinued in symptom-free patients. All patients were on acenocoumarol treatment for at least 4 weeks before the procedure. Periprocedurally, acenocoumarol was not interrupted (target international normalised ratio (INR) 2–2.5) and continued thereafter for at least 3 months.

Hybrid AF ablation procedure

The procedure was performed under general anaesthesia. A double lumen endotracheal tube was placed for selective lung ventilation.

Thoracoscopic procedure

Three thoracoscopic ports were placed on the right side, one 5-mm camera port at the fifth intercostal space (midaxillary) and two working ports in a diamond shape, 5-mm and 12-mm, respectively. Afterwards, the pericardium was opened anterior to the phrenic nerve. The transverse and oblique sinuses were opened with blunt dissection. A track light dissector (Lumitip, AtriCure) was then used to guide a rubber band and position the ablation device (Isolator Synergy Clamps, AtriCure) around the right pulmonary veins (PVs). We ablated the right PVs and then performed ablation of the superior caval vein, using the same bipolar clamp. Ablation for the roof and inferior line of the posterior left atrial box was performed using a linear ablation device (Coolrail,
AtriCure). We tested isolation of the right PVs and the superior caval vein epicardially with a 4-polar catheter (Supreme, St. Jude Medical), with additional ablation if necessary. The left PVs were ablated via a similar left thoracoscopic approach. To complete the posterior box, the roof and inferior line were also made from the left side meeting the ablation lines made from the right side. The isolation of the ablated structures (including the box) was tested again. In patients with previous catheter PV ablation, we tested PV isolation epicardially with the 4-polar Supreme catheter before ablation, but performed epicardial ablation irrespective of whether the PVs were isolated or not. Finally, in patients with CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 [doubled], diabetes mellitus, prior stroke [doubled]-vascular disease, age 65–74, sex category) scores of 2 or higher, we performed surgical exclusion of the left atrial appendage (LAA), using a minimally invasive occlusion device (AtriClip, AtriCure). LAA exclusion did not involve any ablation.
and was performed exclusively for stroke reduction. Oral anticoagulants were resumed after the procedure in all patients according to their CHA2DS2-VASc score, regardless of undergoing LAA exclusion [5].

### Percutaneous procedure

After the surgical procedure, access to the left atrium was established via the femoral vein with a single trans-septal puncture using an 8.5F sheath (Agilis steerable sheath, St. Jude Medical), after which 100E/kg bolus dose of unfractionated heparin was given (target activating clotting time >300 s). Three dimensional electroanatomical mapping was performed using NavX Ensite Velocity (NavX, St. Jude Medical). Electroanatomical maps of the left atrium were created with a circular multipolar catheter (Inquiry optima or Inquiry AFocusII, St. Jude Medical). We performed ablation with an open irrigated 4 mm tip contact force ablation catheter (TactiCath Quartz CF ablation catheter, St. Jude Medical). We performed additional endocardial ablation if the veins were not isolated, surgical lines were incomplete or AF/AFL/AT persisted. In case of AF, complex fractionated atrial electrogram (CFAE) ablation was performed in the left atrium and within the coronary sinus. CFAE was defined as low voltage electrograms having a very short cycle length or fractionation composed of multiple (more than 2) deflections or perturbation of the baseline with continuous deflection of a prolonged activation complex. CFAE detection was done by visual inspection; automated software was not employed. Endpoint of CFAE ablation was conversion of AF to AT/AFL or SR. If AF persisted despite extensive ablation, we performed cardioversion. In case of AT/AFL the arrhythmia was mapped and ablated. Additionally, in all patients, the cavotricuspid isthmus (CTI) line was ablated, or tested for bidirectional block if the patient underwent CTI ablation in the past. Finally, re-induction of AF was attempted using rapid pacing (with cycle lengths as short as 180 ms) in the coronary sinus. Upon induction of AF, we stopped pacing and monitored the duration of AF/AFL/AT. Additional mapping and ablation was performed if sustained AF/AFL/AT was triggered and lasted long enough to allow mapping it (Fig. 1).

### Efficacy and safety endpoints

The primary endpoint was the first AF/AFL/AT recurrence documented by ECG, Holter monitoring (episode lasting more than 30 s), or an event recorder during 12-month follow-up, excluding recurrences occurring in the first 90 days (blanking period) [14]. The secondary endpoints were safety and patient’s quality of life. Safety was defined as the absence of any complications as described by the 2017 expert consensus statement on catheter and surgical ablation of AF [15], quality of life assessment was assessed using the European Heart Rhythm Association (EHRA) score, the Toronto AF Severity Scale (AFSS) and Short Form 36 questionnaires (SF-36).

### Statistical analysis

Patient and procedural characteristics are given as mean ± standard deviation or median and interquartile range for continuous variables and as number of patients with percentages for categorical variables. Kaplan-Meier plot and univariate cox-regression analysis were used to show and compare outcomes. Analysis was done using R package (version 3.4.3), and a $p$-value smaller than 0.05 was considered statistically significant.

### Results

#### Clinical characteristics

Tab. 1 shows the baseline clinical characteristics. Mean age was 57 ± 9 years, 38 (76%) patients were men, five (10%) had paroxysmal, 34 (68%) persistent and 11 (22%) long-standing persistent AF. Time since first AF diagnosis was 5.1 (2.1–8.4) years and 25 (50%) patients had prior failed catheter ablation(s).

---

### Table 3

| Results after 1-year follow-up | all patients (n= 50) |
|-------------------------------|----------------------|
| sinus rhythm maintenance | 38 (76%) |
| total recurrences | 12 (24%) |
| atrial fibrillation recurrences | 3 (6%) |
| atrial flutter recurrences | 9 (18%) |
| antiarrhythmic drug use at 1 year | 2 (4%) |
| endocardial re-ablation | 7 (14%) |
| electrical or chemical cardioversion | 9 (18%) |

---

### Table 4

| Results after 1-year follow-up. List of the major procedural complications | all patients (n= 50) | recovered without sequelae |
|---------------------------------------------|----------------------|--------------------------|
| total major complications | 7 (14%) | 4 (8%) |
| bleeding requiring thoracotomy | 2 (4%) | 2 (4%) |
| permanent phrenic nerve paralysis | 2 (4%) | 0 (0%) |
| pericardial and pleural effusion | 1 (2%) | 1 (2%) |
| pleural effusion | 1 (2%) | 1 (2%) |
| pacemaker implantation | 1 (2%) | 0 (0%) |
| mortality | 0 (0%) | - |

---

### Table 5

| Results after 1-year follow-up. Success at 1-year follow-up | all patients (n= 50) |
|----------------------------------------------------------|---------------------|
| sinus rhythm maintenance | 38 (76%) |
| total recurrences | 12 (24%) |
| atrial fibrillation recurrences | 3 (6%) |
| atrial flutter recurrences | 9 (18%) |
| antiarrhythmic drug use at 1 year | 2 (4%) |
| endocardial re-ablation | 7 (14%) |
| electrical or chemical cardioversion | 9 (18%) |

---

*Off antiarrhythmic drugs and without re-ablation and was performed exclusively for stroke reduction.*
**Procedural data**

Tab. 2 and Fig. 2 show the procedural data. Two (4%) patients did not undergo the endocardial procedure due to bleeding during epicardial ablation necessitating thoracotomy. Additionally, six patients had a pacemaker or an implantable cardioverter defibrillator and therefore superior caval vein ablation was not performed to avoid damaging the leads. In all patients, all PVs were isolated following surgical ablation. In 27 (54%) patients, endocardial mapping demonstrated posterior box isolation after the epicardial procedure. In 21 (42%) patients, additional endocardial ablation resulted in complete box isolation. In 7 (14%) of these 21 patients only the superior line was incomplete after the epicardial procedure, in 3 (6%) patients only the inferior line was incomplete, and in 11 (22%) patients gaps were found in both the superior and inferior lines. In 2 (4%) patients endocardial mapping was not performed due to a bleeding complication resulting in thoracotomy (see Fig. 2).

**Efficacy**

At 1-year follow-up, 38 (76%) patients maintained SR following hybrid AF ablation. Recurrent atrial arrhythmias occurred in 12 (24%) patients. The majority of these recurrences (9 patients) were atypical AFL, with the remaining 3 patients having AF recurrences. Seven of these nine patients with AFL recurrences underwent endocardial re-ablation, six of them completed at least 6 months of follow-up and all six maintained SR until their last follow-up. The seventh patient had
Scores and results at baseline and 1 year. a Average EHRA score at baseline and 1 year. b Results of AF Severity Scale questionnaire at baseline and 1 year. (EHRA European Heart Rhythm Association, AF atrial fibrillation)

Fig. 4

Original Article

to undergo a second endocardial re-ablation due to quick recurrence of AFL. Overall, only two (4%) patients used AADs at 1 year, both had earlier AF/AFL recurrences (Tab. 3).

Safety

Seven (14%) patients suffered complications during and after the procedure. Two (4%) had bleeding during the epicardial procedure necessitating thoracotomy; one due to an injury to the pulmonary artery and the other due to injury to the right inferior pulmonary vein. Both patients recovered completely without any sequelae. Two (4%) had permanent phrenic nerve injury, 1 (2%) developed pericardial and pleural effusion requiring drainage, 1 (2%) pleural effusion requiring drainage, and 1 (2%) was known with a latent sick sinus syndrome before the procedure, requiring a DDD-pacemaker after restoration of SR. Total hospital stay was 6 ± 2 days (Tab. 4).

Determinants of success

Success of hybrid AF ablation showed a significant association with type of AF at baseline (100% in paroxysmal AF versus 79% in persistent AF versus 55% in long-standing persistent AF; \( p=0.039 \); Fig. 3a and b) and history of previous failed catheter ablation (90%
Fig. 4  (Continued)  c  Re-
sults of Short Form 36 ques-
tionnaire at baseline and
1 year.  (EHRA European
Heart Rhythm Association,
AF atrial fibrillation)

versus 62% for patients without previous catheter ab-
lation, \( p=0.020 \); Fig. 3c).

Quality of life

The EHRA score (Fig. 4a), the AFSS questionnaire
(Fig. 4b) and the SF-36 questionnaire (Fig. 4c) at
1-year follow-up all showed significant improvement
compared with baseline, predominantly in patients
who maintained SR.

Discussion

Our study showed that in patients with previous failed
catheter ablation or persistent AF, single-stage hybrid
AF ablation was successful in 76% of patients off AADs
at 1-year follow-up. Success was significantly lower in
patients with long-standing persistent AF. Endocardial
touch-up was needed in 42% of patients to achieve
posterior box isolation. We have included posterior
box isolation as an endpoint for the procedure, be-
cause this area is more likely to harbour AF triggers or
drivers, especially in patients with persistent AF [16],
or contain substrate for re-entry, because of its prox-
imity to the pulmonary veins and its complex fibre
orientation [17]. Therefore, isolating the posterior box
may contribute to a better outcome by eliminating
these AF drivers and reducing the area of the atrial tis-
sue capable of sustaining AF. Additionally, all variants
of Maze-like procedures have posterior box isolation
as a part of their protocol [18].

Two earlier studies reported on single-stage hybrid
AF ablation in 50 patients or more. Pison et al. [12]
described 74% success off AADs in 78 patients and
Gehi et al. [19] reported a 66% success rate in 101 pa-
tients, including patients with concomitant AAD ther-
apy. Our study population was comparable with the
former study, but was younger and had less co-mor-
bidities than the latter.

Our complication rate was higher than both Pison
et al. (8%) and Gehi et al. (6%) [12, 19] reported in
hybrid ablation but lower than Boersma et al. in the
FAST trial (23%) for minimally invasive surgical AF ab-
lation [20]. Important to note here that Gehi et al. re-
ported two deaths, while no mortality was observed
in our cohort. Additionally, our complication rate was
higher than the 12% rate reported in a recent contem-
porary endocardial ablation trial (Fire and ICE) [21].
However, multiple endocardial re-ablations may also
increase the cumulative complication risk for endo-
cardial ablation.

In our analysis, type of AF was significantly asso-
ciated with success, i.e. more persistent forms of
AF were associated with poorer outcome. Our find-
ing are not unexpected since long-standing persistent
AF is associated with more extensive structural atrial
changes, driven by associated comorbidities and AF
itself [22]. This renders the ablation lines insufficient
to abolish AF due to the presence of larger atrial area
capable of sustaining AF [23]. In line with this, we ob-
served a trend towards a better outcome in patients
with a shorter episode of persistent AF. Of interest,
our analysis also showed that in patients with one
or more previous failed catheter ablations, including
both paroxysmal and persistent AF patients, hybrid
AF ablation resulted in excellent 1-year arrhythmia-
free follow-up. The success rate for longstanding per-
sistent AF was moderate but higher than reported in
endocardial ablation studies [8, 9]. Of interest, the majority of these recurrences were AFL episodes. Endocardial re-ablation was highly effective, although the follow-up period was relatively short. Finally, quality of life assessment showed significant improvement at 1-year follow-up, especially in the physical parameters. This improvement was, as expected, more pronounced in patients who maintained SR during the follow-up period.

**Limitations**

The number of patients in this analysis is still too small to draw definitive conclusions. Additionally, due to the lack of continuous heart rhythm monitoring during the follow-up period, it is possible that we failed to document some asymptomatic recurrences of atrial arrhythmias.

**Conclusion**

Hybrid AF ablation is an effective treatment for persistent AF or paroxysmal AF after failed catheter ablation, but the risk of procedure-related complications should be taken into consideration. Therefore, accurate patient selection is of utmost importance, weighing the risks of complications against the potential gain in the patient’s quality of life and the chance of success. Patients with paroxysmal AF after failed catheter ablation, or persistent AF with relatively shorter AF episodes appear to be the best candidates.

**Funding** Atrial fibrillation ablation research at our institution was supported by an unrestricted grant from AtriCure. We acknowledge the support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, CVON 2014-9: Reappraisal of Atrial Fibrillation: interaction between hyperCoagulability, Electrical remodeling, and Vascular destabilisation in the progression of atrial fibrillation (RACE V).

**Conflict of interest** Y. Blaauw has received compensation for lectures from AtriCure. M.I.H. Al-Jazairi, M. Rienstra, T.J. Klinkenberg and I.C. Van Gelder declare that they have no competing interests.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiología (SOLAECE). Europace. 2017;19(10):1589–623.
2. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40.
3. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.
4. Marrouche NE, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–27.
5. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.
6. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311(7):692–700.
7. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(1):32–8.
8. Tilz RR, Billing A, Thum AM, et al. Catheter ablation of longstanding persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol. 2012;60(19):1921–9.
9. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812–22.
10. Lim HS, Hocini M, Dubois R, et al. Complexity and distribution of drivers in relation to duration of persistent atrial fibrillation. J Am Coll Cardiol. 2017;69(10):1257–69.
11. Gomes GG, Gali WL, Sarabanda AVL, et al. Late results of Cox maze III procedure in patients with atrial fibrillation associated with structural heart disease. Arq Bras Cardiol. 2017;109(1):14–22.
12. Pison L, Gelsomino S, Luca F, et al. Effectiveness and safety of simultaneous hybrid thorascopic and endocardial catheter ablation of lone atrial fibrillation. Ann Cardiothorac Surg. 2014;3(1):38–44.
13. Edgerton Z, Perini AP, Horton R, et al. Hybrid procedure (endo/epicardial) versus standard manual ablation in patients undergoing ablation of longstanding persistent atrial fibrillation: results from a single center. J Cardiovasc Electrophysiol. 2016;27(5):524–30.
14. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4):528–606.
15. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1–e160.
16. Lim HS, Hocini M, Dubois R, et al. Complexity and distribution of drivers in relation to duration of persistent atrial fibrillation. J Am Coll Cardiol. 2017;69(10):1257–69.
17. Markides V, Schilling RJ, Ho SY, et al. Characterization of left atrial activation in the intact human heart. Circulation. 2003;107(5):733–9.
18. Lai SC, Melby SJ, Voeller RK, et al. The effect of ablation technology on surgical outcomes after the Cox-maze procedure: a propensity analysis. J Thorac Cardiovasc Surg. 2007;133(2):389–96.
19. Gehi AK, Mounsey JP, Pursell I, et al. Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation. Heart Rhythm. 2013;10(1):22–8.
20. Boersma LV, Castella M, van Boven W, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation. 2012;125(1):23–30.
21. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–45.
22. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335–45.
23. Fabritz L, Guasch E, Antoniades C, et al. Expert consensus document: defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol. 2016;13(4):230–7.